Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.

Abstract : Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms. Patients and methods: This phase II study evaluated the response rate of copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle, in patients with indolent or aggressive malignant lymphoma. Archival tumor tissues were used for immunohistochemistry, gene-expression profiling, and mutation analysis. Results: Thirty-three patients with indolent lymphoma and 51 with aggressive lymphoma received copanlisib. Follicular lymphoma (48.5%) and peripheral T-cell lymphoma (33.3%) were the most common histologic subtypes. Most patients (78.6%) had received prior rituximab and 54.8% were rituximab-refractory. Median duration of treatment was 23 and 8 weeks in the indolent and aggressive cohorts, respectively (overall range 2-138). Eighty patients were evaluated for efficacy. The objective response rate was 43.7% (14/32) in the indolent cohort and 27.1% (13/48) in the aggressive cohort; median progression-free survival was 294 days (range 0-874) and 70 days (range 0-897), respectively; median duration of response was 390 days (range 0-825) and 166 days (range 0-786), respectively. Common adverse events included hyperglycemia (57.1%; grade ≥3, 23.8%), hypertension (54.8%; grade ≥3, 40.5%), and diarrhea (40.5%; grade ≥3, 4.8%), all generally manageable. Neutropenia occurred in 28.6% of patients (grade 4, 11.9%). Molecular analyses showed enhanced antitumor activity in tumors with upregulated phosphatidylinositol 3-kinase pathway gene expression. Conclusion: Intravenous copanlisib demonstrated promising efficacy and manageable toxicity in heavily pretreated patients with various subtypes of indolent and aggressive malignant lymphoma. Subtype-specific studies of copanlisib in patients with follicular, peripheral T-cell, and mantle cell lymphomas are ongoing. This trial is registered with number NCT01660451 (Part A).
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : LillOA Université de Lille Connectez-vous pour contacter le contributeur
Soumis le : lundi 7 juin 2021 - 10:11:26
Dernière modification le : mercredi 23 mars 2022 - 15:51:26
Archivage à long terme le : : mercredi 8 septembre 2021 - 18:12:41


Publication financée par une institution


Distributed under a Creative Commons Paternité - Pas d'utilisation commerciale 4.0 International License




Martin Dreyling, Franck Morschhauser, Kamal Bouabdallah, D Bron, David Cunningham, et al.. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.. Annals of Oncology, Elsevier, 2017, Annals of oncology, 28, pp.2169-2178. ⟨10.1093/annonc/mdx289⟩. ⟨hal-03251450⟩



Consultations de la notice


Téléchargements de fichiers